Arthneeti

Wanbury Q1 FY27 Share Price & Earnings Call Analysis

₹191.59+0.56% today
Market cap
₹670 Cr
P/E
11.29
ROE
68.39%
PEG
0.10
Price to sales
1.03
Debt to equity
1.57
52W high / low
₹345 / ₹163
Sales growth (5Y)
10.63%
EBITDA margin
15.10%
Net profit margin
10.71%
Promoter holding
42.98%
Sales (last year)
₹653 Cr

Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Wanbury rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Wanbury.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Wanbury

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Wanbury

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +126133146144146139131161133172163160162
Expenses +119119133127124121120141120142139134136
Operating Profit6141317211811201430242627
OPM %5%11%9%12%15%13%8%12%10%17%15%16%16%
Other Income +0-311111212000
Interest786887810109877
Depreciation3333333333444
Profit before tax-315710818119141516
Tax %8%-11%6%-2%-0%3%0%2%5%-6%1%-0%1%
Net Profit +-315710818120131516
EPS in Rs-1.000.311.432.253.142.470.322.450.376.184.104.354.52

Financials of Wanbury

Profit & Loss

Annual income statement trend

Sep 2014 18mMar 2015 6mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +661250420432370391367392511500578600658
Expenses +620228387414438375344374475476506523551
Operating Profit41213419-6816231836237277107
OPM %6%9%8%4%-18%4%6%5%7%5%12%13%16%
Other Income +-2376090769842770133
Interest48193236314033232121293731
Depreciation235910101010101112131314
Profit before tax-2674-762-32-2565-1281-10313064
Tax %1%28%0%1%-1%-1%0%2%-0%1%1%-3%
Net Profit +-2703-762-32-2564-1381-10303165
EPS in Rs-135.211.61-3.5226.71-13.49-10.4825.79-5.0424.94-3.189.289.3219.15
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Wanbury

Balance Sheet

Capital structure and asset base

Sep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital20202023242425253333333335
Reserves-186-188-183-151-183-207-143-156-30-40-52672
Borrowings +3893813732732242331641667468116179196
Other Liabilities +182182176265207235231253275241199176153
Total Liabilities404394386411271285277288351302343414457
Fixed Assets +174164180186178172164167167167167201199
CWIP131914101091411223513
Investments0000000000000
Other Assets +2182121922158310399109182133173208244
Total Assets404394386411271285277288351302343414457

Financials of Wanbury

Cash Flows

Operating, investing and financing cash movement

Sep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +74404343323044174120526
Cash from Investing Activity +-7-5-20-13-1-36481-9-17-51
Cash from Financing Activity +-75-30-28-27-33-27-108-17-29-321426
Net Cash Flow-95-53-2-0-0713-2121
Free Cash Flow6235222930253612427-9-23
CFO/OP180%187%129%234%-49%188%188%97%113%86%7%35%

Financials of Wanbury

Ratios

Working capital efficiency and return ratios

Sep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days5714465712941503245505670
Inventory Days4210369632736254160264347
Days Payable112300171259173208252220218178196172
Cash Conversion Cycle-13-54-37-124-117-131-176-147-112-101-96-55
Working Capital Days-44-139-123-164-251-230-211-227-134-129-374
ROCE %6%12%55%-1%26%31%23%46%17%58%34%
8out of 100

Momentum score · price trend

8 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months−27.5%26%
Last 6 months−24.8%13%
Last 3 months−33.4%2%

The price is 44.7% below its all-time high of ₹344.75 (15 Jul 2026). Stocks more than 20% below their peak have their score halved, so 16 became 8.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Wanbury: 0.4 × 26 + 0.4 × 13 + 0.2 × 2 = 16, halved to 8 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Wanbury's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals